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It is surprising that, while arsenic trioxide (ATO) is now considered as “the single most active agent in patients with acute 
promyelocytic leukemia (APL)”, the most important discoverer remains obscure and his original papers have not been cited by 
a single English paper. The discovery was made during the Cultural Revolution when most Chinese scientists and doctors 
struggled to survive. Beginning with recipes from a countryside practitioner that were vague in applicable diseases, Zhang 
TingDong and colleagues proposed in the 1970s that a single chemical in the recipe is most effective and that its target is APL. 
More than 20 years of work by Zhang and colleagues eliminated the confusions about whether and how ATO can be used ef-
fectively. Other researchers, first in China and then in the West, followed his lead. Retrospective analysis of data from his own 
group proved that APL was indeed the most sensitive target. Removal of a trace amount of mercury chloride from the recipe 
by another group in his hospital proved that only ATO was required. Publication of Western replication in 1998 made the 
therapy widely accepted, though neither Western, nor Chinese authors of English papers on ATO cited Zhang’s papers in the 
1970s. This article focuses on the early papers of Zhang, but also suggests it worth further work to validate Chinese reports of 
ATO treatment of other cancers, and infers that some findings published in Chinese journals are of considerable value to pa-
tients and that doctors from other countries can benefit from the clinical experience of Chinese doctors with the largest popula-
tion of patients. 
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Acute promyelocytic leukemia (APL) had been one of the 
most aggressive and fatal forms of acute leukemia, but is 
now one of the most treatable form of leukemia. While 
there are still room for improvement in treating APL, sig-
nificant progress has been made in the last few decades by 
the applications of cytarabine (arabinosyl cytosine, Ara-C) 
[1], anthracyclines [2–4], arsenic trioxide (As2O3, ATO) 
[5–8] and all-trans retinoic acid (ATRA) [9,10]. 
The discoveries of cytarabine, anthracyclines and ATRA 
are well known, whereas the history of the discovery of 
ATO therapy remains unknown. Most APL researchers cit-
ed papers published in the 1990s, which were 20 years later 
than the original papers. Some authors also seem to be con-
fused about the original discoverer of ATO. These mistakes 
are regrettable when ATO is now considered to be “the 
most biologically active single drug in APL” by a panel of 
International Leukemia Experts for the European Leuke-
miaNet [11] or “the single most active agent in patients with 
APL” [12] and that the combination of ATO and ATRA 
holds the promise to “replace conventional approaches for 
most, if not all, patients in the very near future” [12]. The 
past decade has witnessed the general acceptance of ATO 
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[13] and accumulating proof of more ATO applications 
from relapsed APL to newly diagnosed APL [14,15].  
Ignorance of, and confusions about, the early work result 
in part from the fact that the original papers were published 
in the Chinese language and in journals that are obscure 
even to most Chinese readers, although there are other fac-
tors of a more complex nature. This article summarizes the 
early papers from the discovery of ATO treatment of leu-
kemia to the general acceptance of the use of ATO in treat-
ing APL. We also provide a list of the early papers in Eng-
lish for Western authors to use in citations.  
We note that the authors of the present article have not 
worked on leukemia and write this article in our roles as 
researchers in the history of science. We hope that those 
working on leukemia can go into more details of the origi-
nal work. 
1  Cultural milieu and historical peculiarities of 
the discovery 
In the 1960s and early 1970s, China was in a political tur-
moil known as the Great Proletarian Cultural Revolution. 
Although its origins lie in the political intentions of Mao 
ZeDong, the supreme leader of China at the time, the Cul-
tural Revolution has affected more than one generation of 
Chinese people directly and indirectly. Some would view 
what is happening in China now in part as a consequence of, 
or a reaction to, the Cultural Revolution, with most viewing 
the Cultural Revolution as negative, if not disastrous. 
Of the many leftist policies during the Cultural Revolu-
tion, most were harmful, but some had mixed or even posi-
tive effects intended or unintended by the policy maker(s). 
One policy directly related to Mao was to improve the 
medical conditions of rural China by sending doctors from 
urban hospitals to the countryside in “Circulating Medical 
Teams”. Doctors in such teams will go to multiple villages 
and members of the team will rotate. Another policy was to 
emphasize the importance of traditional Chinese medicine 
and drugs. The interception of these two led to many claims 
of findings of great effects of some Chinese medicine or 
treatment, most of which were abandoned within a few 
years. However, a few have withstood the test of time. The 
discovery of ATO was one such example. 
Arsenic has been used for a long time, both in China and 
in the West. Several traditional Chinese medical recipes 
contain arsenic, but they were combinations of multiple 
chemicals with unclear targets. Western uses of arsenic 
were also ill-defined [16]. For example, Thomas Fowler of 
Britain invented a solution containing potassium arsenite 
(KAsO2) in 1786, and used it for agues, remittent fevers and 
periodic headaches [16]. After leukemia was discovered in 
1845, Fowler’s solution was used in treating leukemia in 
1865, and again in 1931 [17]. Arsenic and irradiation were 
the main forms of treatment for chronic myelocytic leuke-
mia (CML) until 1953, when they were replaced by chemo-
therapy with busulfan [16,17]. Arsenic treatment of leuke-
mia was no longer a standard drug for leukemia from then 
on. In China, Guan JiRen, a doctor in Harbin Medical Uni-
versity, tried to use Fowler’s solution to treat leukemia in 
1958 and came to the conclusion that it was ineffective [18]. 
In the 1950s and 1960s, Zhou AiXiang in Beijing and Gu 
DeQing in Shanghai used combinations that included arse-
nic sulfate to treat leukemia [19]. It is also doubted that ar-
senic sulfate can be turned into ATO because the prepara-
tion of the Chinese medicine did not involve the high tem-
perature required for the conversion of arsenic sulfate into 
ATO. In 1972, a report appeared in Anti-Cancer Battle 
News of Liaoning Province, a publication explicitly labeled 
as “internally circulated materials” under the authorship of 
Chaoyang People’s Hospital Department of Pediatrics [20]. 
It reported the treatment of 16 cases of acute granulocytic 
leukemia children by a combination of arsenic and chemo-
therapy. Because this treatment did not separate arsenic 
from the chemotherapy available then, it was unclear 
whether arsenic was helpful as an addition to chemotherapy, 
nor was it known how effective the combination was: suc-
cess rate among the 16 patient was not reported and blood 
analysis was shown for only one patient [20]. A 1974 re-
view by the Chinese Academy of Traditional Medicine 
summarized different approaches and medicines for leuke-
mia treatment by traditional Chinese medicine listed As2S3 
and toad venom (and others, including pure chemicals of 
Western invention) [21]. It cited [19] and [20] as supporting 
the use of As2S3. It should be noted that neither Gu nor 
Zhou has reduced their recipes to a single component, even 
today [22]. Because the preparation and processing of the 
Chinese medicine containing As2S3 did not involve the high 
temperature required for the conversion of arsenic sulfate 
into ATO, the relation of arsenic sulfate with ATO in such 
recipes is unclear. The 1974 review did not provide a con-
clusive recommendation on the type of Chinese medicine 
for the treatment of leukemia. Toad venom and quite a 
number of other medicines discussed in that review have 
not become a standard therapy for any type of leukemia. In 
summary, by 1974, it was unclear which of the traditional 
Chinese drugs can be used to treat leukemia and the effec-
tiveness of those tested by then were uncertain. 
In the early 1970s, Han TaiYun, a pharmacist of the First 
Affiliated Hospital of Harbin Medical University, was a 
member of a circulating medical team. He learned that a 
countryside practitioner of traditional Chinese medicine 
used a combination of arsenic, mercury and toad venom to 
treat lymphatic tuberculosis and cancers. In March 1971, 
Han made a solution that contained these three components, 
which he called “713” (after the year and month of his 
preparation) or “Ailin (literally meaning cancer effective)”. 
Intramuscular injection showed effects in some cancer pa-
tients. The “713” solution was hotly sought after locally for 
a while but faded soon from the public because of its tox-
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icity. The target diseases of 713 were undefined, nor were 
the active chemical in 713. 
Zhang TingDong was a doctor in the same hospital as 
Han. Zhang was born in 1932 and graduated in the 1950s 
from Harbin Medical University, after studying the regular 
(Western) medicine. He took classes of traditional Chinese 
medicine in the 1960s. He worked in the Department of 
Traditional Chinese Medicine of the First Affiliated Hospi-
tal of Harbin Medical University. He was initially asked by 
the Health Bureau of the Heilongjiang province to examine 
the validity of the claims of the countryside practitioner and 
later collaborated with Han. 
2  Original discovery of the effective treatment 
of APL by ATO: 1973–1979 
After 1972, Zhang and colleagues focused their research on 
leukemia. They also analyzed the components of “713” and 
suggested that arsenic was solely responsible for the thera-
peutic effect, whereas mercury caused kidney toxicity and 
toad venom caused hypertension. Neither of the latter two 
was therapeutically useful for leukemia. From then on, their 
recipe of Ailin I was mainly arsenic trioxide and a trace 
amount of mercury (at a ratio of 100:1 by weight), without 
toad venom. 
The first paper by Zhang and Han was published in 1973 
in a local Chinese journal. Zhang TingDong, Zhang PengFei, 
Wang ShouRen and Han TaiYun reported that they had 
used “Ailin solution” (also known as “Ailin I”) to treat six 
cases of chronic granulocytic leukemia [5]. They explicitly 
stated that the components of the solution were ATO and a 
trace amount of mercury chloride. All six patients improved 
after the treatment. They also mentioned that acute leuke-
mia patients were being treated, but with no results in that 
paper.  
In 1974, under the collective institutional authorship of 
the Department of Traditional Chinese Medicine and the 
Department of Laboratory Medicine of Harbin Medical 
University, they published a report in the university journal 
[6], summarizing the treatment of 17 cases of leukemia pa-
tients from January 1973 to April 1974. After going through 
different types of leukemia, they reported that Ailin I was 
effective in treating multiple types of leukemia, leading to 
complete remission (CR) in acute leukemia patients. In 
1976, they used an institutional authorship to publish a re-
port on five cases of acute leukemia in which they had 
achieved CR.  
In 1979, Rong FuXiang and Zhang published two cases 
of acute granulocytic leukemia, one with CR for four and a 
half years and the other for three years [7].  
A second paper by Zhang and Rong in 1979 summarized 
their treatment results from 55 cases of acute leukemia [8]. 
Twenty-three leukemia patients were treated with Ailin I 
alone (from 1973 to 1974), 20 were treated with Ailin I in 
combination with Western chemotherapy and other Chinese 
medicines from 1975 to 1976, and 12 treated with Ailin I 
plus other Chinese medicines and chemotherapy from 1977 
to 1978. For each patient, they presented leukemia subtypes 
and clinical observations. All 55 cases improved to some 
extent, with a remission rate of 70% and with CR in 12 cas-
es. Side effects were small with the doses they used. They 
then applied 10 times the equivalent of what they used for 
adult human patients to 12 rabbits. No toxicity was ob-
served in the heart, the liver, the spleen or the kidney of the 
rabbits.  
While the 1973 paper reported their pioneering findings, 
the second 1979 paper represented their understanding of 
the therapeutic effect [8]. There are three important ques-
tions about early work of Zhang and colleagues: (i) Had 
they shown that the therapeutic effect came from Ailin I, but 
not from other Western chemicals or Chinese medicines? (ii) 
Had they realized that the effect of Ailin I came from ATO 
but not from mercury in the solution? (iii) Had they known 
the effect of ATO on APL?  
Answers for all three questions can be found in [8] which 
explicitly stated that (i) significant improvement was ob-
served in three patients (one adult and two children) using 
only Ailin I, but no other Western or Chinese drugs. At the 
time of publication, the children had survived for more than 
four years and the adult more than nine months. When using 
other Chinese medicines, Zhang and Rong pointed out that 
those were not used for treatment of leukemia, but for sup-
porting the general health of the patients so that they could 
tolerate more treatments; (ii) the effective component of 
Ailin I was ATO (on page 11 of their paper); (iii) acute 
granulocytic leukemia (M3 type of the French-American 
British FAB classification, also known as APL) was the 
most sensitive to the treatment, which was a conclusion 
reiterated on pages 10 and 11 of their paper.  
We can see that, by 1979, Zhang and his collaborators 
had clearly reached our current understanding that ATO 
could treat leukemia, especially that of the M3 subtype or 
APL. 
3  Further studies by the Zhang group from the 
1980s to the 1990s 
In 1981, a paper under an institutional authorship with a 
footnote indicating Zhang as the supervisor (with eight oth-
er authors) reported 73 cases of acute granulocytic leukemia 
patients, with a CR of 24% and remission rate of 86% after 
Ailin I treatment [23]. In 1982, Zhang and Li presented a 
report to a national meeting on 22 cases of CR by Ailin I 
and on 98 cases of non-lymphatic leukemia. In 1982 and 
1983, Zhang published reviews of his work [24,25]. 
In 1984, Zhang and Li [26] published a summary of 81 
cases which they had treated since 1971. Among the 22 
cases of CR, they pointed out that seven were of the M2 
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type and 15 were of the M3 type. They again stated that the 
effect on M3 type was particularly obvious. Zhang [27] 
published another paper on the effect of Ailin I on 
non-lymphatic acute leukemia. 
In 1991, Sun et al. [28] continued the work of Zhang and 
Li [26]. They reported that Ailin I had been used to treat 32 
APL cases from 1974 to 1985, with CR in 19 cases and that 
16 cases had survived for more than five years. This con-
firms the high success rate for ATO treatment of APL. 
In 1992, Sun et al. [29] published a short “Sharing Expe-
rience” paper, reviewing materials identical to the 1991 
paper. Oddly, most English papers cite this 1992 paper for 
the discovery of ATO treatment of APL, although both pa-
pers were in Chinese.  
Because Zhang TingDong’s papers from the 1970s to the 
early 1990s included a trace amount of mercury chloride, in 
addition to ATO (at a ratio of 1:100 by weight), strictly 
speaking, they had not proven that mercury chloride did not 
have a positive effect, despite the fact that their 1973 paper 
had mentioned that only ATO was the effective ingredient 
in Ailin I. 
In 1995 and 1996, Zhang Peng and colleagues from the 
same hospital as Zhang TingDong published two papers 
which showed the effectiveness of ATO alone without 
mercury [30,31]. The 1995 paper was an abstract, which did 
not explicitly state that mercury chloride was not included 
in the 713 solution, although Zhang later said that they used 
only ATO. The 1996 paper did show that ATO, but not 
mercury chloride, was used. They treated 130 APL patients 
from 1992 to 1995, among which 72 went through one or 
more courses of treatment. A CR of 73% was observed in 
patients undergoing initial treatments and 52% in recurrent 
patients [31].  
In the process of uncovering the history of ATO research, 
we found no evidence that leukemia classification by tradi-
tional Chinese medical theories was useful for discovering 
the target of ATO. Here we separate traditional Chinese 
medicine into drugs and theories. Had the traditional Chi-
nese medical theories (CMTs) been helpful for developing 
ATO as a treatment for leukemia? Zhang and colleagues 
discussed five types of leukemia based on CMT classifica-
tion, there was no difference of ATO on different CMT 
types [68]. In this regard, the Western classification of 
leukemia was helpful. When they completely gave up the 
CMT classification, the effect was more obvious. Interest-
ingly, their first paper in 1973 did not mention CMTs, but 
their later papers in the 1970s and 1980s did. Lack of evi-
dence for the utility of CMTs does not disprove the CMTs, 
but it is so far unclear whether the CMTs are important or 
essential for scientific studies of traditional Chinese drugs. 
4  Chinese contributions to APL treatment 
Anthracyclines (including daunorubin) and cytarabine be-
came frontline treatment for APL because of research in 
the West [1–3]. Chinese contributions in the discoveries of 
ATO and ATRA came after those, but have significantly 
improved APL treatment. Here we place the Chinese dis-
coveries in the historical context. 
In 1973, Zhang and colleagues of China reported the 
therapeutic effect of ATO on leukemia [5], and Zhang and 
Rong [8] in 1979 suggested that APL was particularly sen-
sitive to ATO. 
In 1977, Collins et al. [32] at the NCI successfully estab-
lished a cell line (HL-60) from an APL patient. Collins et al. 
used it to screen for chemicals which could induce the dif-
ferentiation of HL-60 cells to mature into normal cells. In 
1980, Breitman et al. [33] discovered that all-trans retinoic 
acid (ATRA) and 13-cis retinoic acid induced HL-60 dif-
ferentiation into mature cells. Related chemicals such as 
Vitamin A was 1000 fold less effective. They suggested that 
“this compound could provide a new therapeutic tool in the 
treatment of acute myeloid leukemia”. 
In 1981, Breitman et al. [34] tested drug sensitivity of 
leukocytes from the peripheral blood of leukemia patients 
and found that cells induced to differentiate by ATRA all 
came from two patients with APL. Olsson and Brietman [35] 
in 1982 showed that retinoic acid could also induce U-937 
lymphoma cells to differentiate. In 1983, Honma et al. [36] 
from Japan reported the effects of multiple chemicals on 
inducing differentiation of cells from different leukemia 
patients, and found that ATRA was among those capable of 
inducing the differentiation of leukocytes from APL pa-
tients. Koeffler [37] in 1983 summarized in vitro studies 
including cellular differentiation by retinoic acid and other 
chemicals, viewing ATRA and 13-cis retinoic acid as 
equivalent in differentiating APL leukocytes. 
Single cases of APL treatment by 13-cis retinoic acid 
were reported by four groups: Flynn et al. [38] in 1983 from 
Minnesota, USA; Nilsson [39] in 1984 from Lund, Sweden; 
Daenen et al. [40] in 1986 from the Netherland; and Fon-
tana et al. [41] in 1986 from west Virginia, USA. 
In 1985, Wang Zhen-Yi of Shanghai Second Medical 
College could obtain ATRA (but not 13-cis retinoic acid) 
from a local source. He used it to successfully treat a 
five-year-old girl. In 1987, his group published a paper in 
the English edition of the Chinese Medical Journal, report-
ing the use of ATRA (alone or in combination) for the 
treatment of six APL patients [9]. In 1988, Wang’s group 
published their use of ATRA in the treatment of 24 APL 
patients in Blood [10]. It cited Breitman et al. [33,34] and 
Koeffler [37], which reported the effects of ATRA and 
13-cis retinoic acid on inducing the differentiation of leu-
kemia leukocytes, as well as Flynn et al. [38], Nilsson [39], 
Daenen et al. [40], and Fontana et al. [41] which reported 
treatment of APL patients by 13-cis retinoic acid. 
Huang et al. [10], but not Huang et al. [9] (both in Eng-
lish, but the 1988 paper published in the US and the 1987 
paper in China), drew international attention. Direct com-
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munication with French doctors also helped. The finding of 
Wang group with ATRA were soon replicated. In 1989, 
Chomienne et al. [42] from France compared the effects of 
ATRA and 13-cis retinoic acid with two APL patients for 
each chemical and felt that ATRA were more effective. In 
1990, the same French group, after working with leukocytes 
from 22 APL patients in vitro, concluded that ATRA was 
10 times more effective than 13-cis retinoic acid [43]. The 
effect of ATRA was also confirmed by Chinese doctors 
(e.g., Chen et al.) [44]. In 1991, Warrell et al. [45] in the US 
replicated the findings of the Wang group in China and the 
Degos group in France with nine out of 11 APL patients 
successfully treated by ATRA. Since then, ATRA was well 
recognized for APL treatment. In 1997, Tallman et al. [46] 
reported their studies of 346 APL patients, in which they 
compared the therapeutic effects of ATRA and the previ-
ously standard chemotherapy with daunorubin and cytara-
bine, and found it to be more effective if ATRA was used 
for both induction and maintenance. 
In 1992, Duan et al. [47] published in vitro studies of the 
effect of ATO on leukemic cells. In 1995, Huang and 
coworkers from Dalian, China reported that a tablet with 
multiple components derived from traditional Chinese 
medicine (herbs and minerals) led to 98% CR in 60 APL 
patients [48]. One of the components contained arsenic di-
sulfide.  
In 1995 and February 1996, Zhang Peng and colleagues 
from Harbin reported their success in using ATO in achieving 
73% of CR in 130 APL cases from 1992 to 1995. No cross-     
resistance was observed between ATO and ATRA [30,31].  
In August 1996, Chen GuoQiang and 18 other authors 
(including Zhang TingDong in the middle and Chen Sai-
Juan, Wang Zhen-Yi and Chen Zhu as the last authors) re-
ported work from Shanghai Hematology Institute that used 
in vitro culture leukemic cells for mechanistic studies of the 
therapeutic effect of ATO on leukemia at the molecular  
level [49]. 
In 1997, Xu JingShu, Duan JingMian, Xu Ying, Xin 
XiaoMin, Song XiaoHong and Zhang TingDong reported a 
case of who had recurrent APL three times [50]. The patient 
was treated with Ailin I every time and had survived for 20 
years. 
In 1997, Chen et al. [51] from Shanghai published 
dose-dependent effect of ATO on leukemic cells in 
vitro. Shen et al. [52] from Shanghai reported that they 
used pure ATO to treat 15 APL patients, among which 10 
cases with only ATO. CR was achieved in 90%.  
In 1998, Soignet et al. [53] from the Memorial 
Sloan-Kettering Cancer Hospital and Cornell Medical Col-
lege reported in the New England Journal of Medicine that 
they had treated 12 recurrent APL cases with ATO and ob-
served CR in 11 cases. The mechanisms were thought to be 
partial cellular differentiation and apoptosis.  
The Soignet et al. paper helped general international ac-
ceptance of ATO as a treatment of APL, which could not be 
achieved by many papers published in China by Chinese 
doctors over the previous two decades. 
5  Lack of recognition 
ATO has now been well accepted (and generally used) na-
tionally and internationally, saving lives in China and other 
countries. However, the discoverer remains largely un-
known in academic and medical communities, although 
there was a 2001 story about him in the New York Times 
[54]. It is more striking that, while the discovery of the ef-
fect of ATRA on APL has led to both national and interna-
tional awards to Wang Zhen-Yi, not a single national or 
international award has been given to Zhang TingDong or 
any of his Harbin colleagues for the discovery of the thera-
peutic effect of ATO on APL, although ATO was discovered 
more than a decade before ATRA and is recognized as “the 
most biologically active single drug in APL” by International 
Leukemia Experts for the European LeukemiaNet [11]. 
The reason for lack of recognition is not due to contro-
versies. There was a patent contention by Hongde Sun, a 
member of Zhang’s group. It was quite late and the judge 
ruled in Zhang’s favor. Peng Zhang insisted that he was the 
first to show the effect of ATO alone, without mercury. 
Zhang and Rong [8] had suggested that ATO alone was 
effective, but they had not shown data with ATO alone. 
Both Sun and Zhang Peng have made important contribu-
tions, but it is clear that Zhang TingDong has played an 
undisputed key role in his persistent work from the 1970s to 
the early 1990s which turned the often fuzzy arsenic treat-
ment with variable results into practically useful treatment 
with beneficial effects. 
In 1998, Chen et al. [55] published in a Chinese journal 
that “from the early 1970s, Harbin Medical University dis-
covered through clinical practices that arsenic trioxide could 
effectively treat APL. In the past two years, we have col-
laborated with HMU and used arsenic trioxide solution to 
treat APL patients resistant to ATRA and conventional 
chemotherapy”, affirming the work and priority of Harbin, 
though Zhang’s name and papers in the 1970s did not ap-
pear in the review [55].  
Almost no English paper realized that Zhang had pub-
lished his findings from 1973 to 1979. English papers, in-
cluding those by Chinese scholars, only cited Sun et al. [29] 
and sometimes Zhang Peng et al. [31] as the first paper(s) 
for ATO treatment of leukemia. For example, Soignet et al. 
[53], which replicated the findings of Zhang in the 1970s 
and played a major role in the international acceptance of 
ATO treatment for APL, mentioned “recent Chinese re-
ports” of CR in APL by ATO, and cited only Sun et al. [29], 
Zhang Peng et al. [31], and Shen et al. [52]. It is impossible 
to know from the Soignet et al. paper that the original find-
ings were made in the 1970s by Zhang TingDong because 
both the tone and the citations made it seem that Chinese 
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discoveries were made in the 1990s. 
A 1996 news report in Science did mention Zhang [56], 
but stated that Zhang published his paper in 1992.  
Zhang has published few English papers. In 2001, he and 
Chen GuoQiang were co-first authors (with Wang Zhen-Yi, 
Chen SaiJuan in the middle and Chen Zhu as the corre-
sponding author) of a review about ATO in an international 
journal Oncogene [57]. In the introduction, they stated “re-
cent” studies of ATO treatment of APL, citing the 1996 
paper of Chen et al. [49]. On the second page, they stated 
that the research on ATO began in 1971, without citing any 
publications, and that they had treated more than a thousand 
patients of different types of cancers including “chronic 
granulocytic leukemia, lymphoma, esophageal cancer, and 
particularly APL”, but again without citing any literature. 
Thus, Zhang, presumably as the first author of an English 
paper, neglected to cite his own early papers, effectively 
burying the pioneering findings in the 1970s.  
In 2002, Zhu et al. [58] published a review in Nature 
Reviews Cancer. In the figure illustrating milestones in APL 
treatments, Zhang TingDong in the 1970s were placed, but 
the citation in the text was Sun et al. [29] and the explana-
tion in the reference list credited Sun et al. [29] as “first 
report of As2O3 therapy in APL”. 
Both Sun et al. [29] and Zhang et al. [31] were published 
in Chinese, and neither of them cited papers from the 1970s. 
Thus, even if any international scholars attempted to obtain 
English translations of the 1992 and 1996 papers, they 
would not know the original 1970 papers. 
In 2008, Wang Zhen-Yi and Chen Zhu [59] reviewed 
progress in APL treatment in Blood, with its first citation of 
ATO as the Zhu et al. [58] review, and further citations for 
ATO treatment of APL being Sun et al. (1992) [29], Zhang 
et al. (1996) [31], Chen et al. (1996) [49], Shen et al. (1997) 
[52] and Niu et al. (1999) [60].  
In 2011, Chen et al. [61] published a review of the ther-
apeutic effect of ATO on leukemia, which stated “in the 
early 1970s, a group from Harbin Medical University in 
northeastern China tested Ailing-1 containing 1% ATO and 
a trace amount of mercury chloride in a variety of cancers 
by intravenous administration”, without mentioning the 
researchers or citing papers of the 1970s. The review then 
cited Sun et al. (1992) [29] for showing that “Ailing-1 in-
duced CR in 21 of 32 patients with APL with an impressive 
10-year survival rate of 30%” before stating that “the effi-
cacy of pure ATO in treating relapsed APL was then re-
ported by Shanghai Institute of Hematology (SIH) in 
1996–1999”, citing Shen et al. (1997) [52] and Niu et al. 
(1999) [60], ignoring the papers of Zhang Peng et al. from 
Harbin Medical University who had published a paper in 
1995 and one in 1996 [30,31], which stated that they had 
used ATO alone (without a trace amount of mercury chlo-
ride).According to a 2013 blog by Zhang Peng, his results 
were known to Chen and others who attended a national 
meeting in 1995 [62]. 
A 2011 paper on a 10-year follow-up study of ATO 
treatment of APL published by Au et al. [63] from Hong 
Kong cited a paper published by US authors in 2001.  
Thus, no authors who can read Chinese have cited any of 
the 1970s papers in their English publications. In the current 
climate that English authors do not go to original papers in 
even French or German, it is no wonder that they do not 
know the titles and authors of the original papers published in 
Chinese. The contributions of Zhang TingDong and the pre-
cise timing of his discovery are therefore virtually unknown 
in the international academic and medical communities. 
6  Implications of paying attention to work pub-
lished in Chinese 
In the past, there is a general negligence of clinical studies 
carried out in China. Language is only part of the reason. 
With the large number of patients in China, many doctors in 
China have more clinical experience than most doctors in 
Western countries. Some, even though a small fraction of, 
Chinese doctors may have insights into treatments that they 
have only published in Chinese journals. 
In the case of ATO, for example, Chinese doctors in-
cluding Zhang and others have reported ATO treatment of 
multiple cancers, from liver, stomach and colon cancers to 
lymphomas [64–66]. These are worth further test and vali-
dation. 
An indirect inference is that rigorous studies of compo-
nents of Chinese medicine may lead to more discoveries. 
For example, drugs used tentatively by Chinese hospitals or 
marketed aggressively by Chinese companies (without prior 
stringent tests), may prove to be more powerful and specific 
after rigorous studies, and become more internationally ac-
ceptable and will eventually help more patients and save 
more lives. 
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